

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



華潤醫藥集團有限公司

China Resources Pharmaceutical Group Limited

(Incorporated in Hong Kong with limited liability)

(Stock Code: 3320)

INSIDE INFORMATION
REGISTRATION OF ULTRA SHORT-TERM DEBENTURES
BY THE NATIONAL ASSOCIATION OF FINANCIAL MARKET INSTITUTIONAL
INVESTORS

This announcement is made pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined in the Listing Rules) of Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board of directors (the “**Board**”) of China Resources Pharmaceutical Group Limited (the “**Company**”, and together with its subsidiaries, the “**Group**”) is pleased to announce that China Resources Pharmaceutical Holdings Company Limited (華潤醫藥控股有限公司) (“**CR Pharmaceutical Holdings**”), a wholly-owned subsidiary of the Company, has received a notice of acceptance of registration (Zhong Shi Xie Zhu [2017] No. SCP40) (the “**Notice**”) issued by the National Association of Financial Market Institutional Investors in relation to the proposed issuance of ultra short-term debentures (the “**Ultra Short-Term Debentures**”) of up to RMB15 billion by CR Pharmaceutical Holdings in the People's Republic of China (the “**PRC**”). The Notice shall be effective for a period of two years from the issue date of the Notice, during which CR Pharmaceutical Holdings may issue the Ultra Short-Term Debentures in tranches. If the proposed issuance of the Ultra Short-Term Debentures proceeds, it is expected that the proceeds raised therefrom will mainly be used for the repayment of existing debt of the Group and replenishment of working capital.

The Company will make further announcement in relation to the proposed issuance of the Ultra Short-Term Debentures as and when appropriate.

As the proposed issuance of the Ultra Short-Term Debentures may or may not proceed, shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
China Resources Pharmaceutical Group Limited
WANG Chuncheng
Executive Director

Beijing, the PRC, 23 February 2017

As of the date of this announcement, the Board comprises Mr. FU Yuning as chairman and non-executive Director, Mr. WANG Chuncheng, Mr. SONG Qing and Mr. LI Guohui as executive Directors, Mr. CHEN Rong, Mr. YU Zhongliang, Mr. WANG Chenyang and Ms. WANG Jing as non-executive Directors, Mr. TSANG Hing Lun, Mr. KWOK Kin Fun, Mr. FU Tingmei and Mr. ZHANG Kejian as independent non-executive Directors.